Nektar Management to Present at Upcoming Investor Conferences
Nektar Management to Present at Upcoming Investor Conferences
SAN FRANCISCO, May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences:
2024年5月30日，舊金山/PRNewswire/--內克塔治療公司（納斯達克：NKTR）管理層定於出席即將到來的投資者會議:
- Jefferies Healthcare Conference in New York City on Thursday, June 6, 2024 at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time
- Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Monday, June 10, 2024 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time
- Jefferies健康醫療會議將於2024年6月6日（星期四）美國東部時間下午3:30/太平洋時間下午12:30在紐約市舉行。
- 高盛第45屆年度全球醫療保健會議將於2024年6月10日（星期一）美國東部時間下午2:00/太平洋時間上午11:00在邁阿密舉行。
The presentations will be accessible via webcast through links posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. The webcasts will be available for replay until July 6, 2024 and July 10, 2024, respectively.
演示文稿將通過內克塔網站投資者活動部分發布的鏈接，通過網絡廣播進行訪問:https://ir.nektar.com/events-and-presentations/events這些網絡廣播將分別在2024年7月6日和7月10日提供重播。
About Nektar Therapeutics
關於內克塔治療公司
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
內克塔治療公司是一家臨床級別的生物技術公司，專注於開發治療自身免疫和慢性炎症性疾病的藥物。內克塔的主要產品候選藥物rezpegaldesleukin（REZPEG或NKTR-358）是一種新型的、第一類的調節性T細胞刺激劑，目前正在進行兩個2b期臨床試驗，一個是在特應性皮炎中進行，另一個是在脫髮症中進行。我們的研發管線還包括一個臨床前的候選藥物NKTR-0165，這是一種二價的腫瘤壞死因子受體II激動劑抗體。內克塔與各種合作伙伴一起，還在進行多個臨床試驗，評估NKTR-255，一種試驗性的IL-15受體激動劑，旨在增強免疫系統對抗癌症的自然能力。內克塔位於加利福尼亞州舊金山。欲了解更多信息，請訪問www.nektar.com並關注我們的LinkedIn。
Contact:
聯繫方式：
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
對於投資者：
內克塔治療公司的Vivian Wu
628-895-0661
For Media:
David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com
對於媒體人員：
Argot Partners的David Rosen
（212）600-1902
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-management-to-present-at-upcoming-investor-conferences-302160077.html
SOURCE Nektar Therapeutics
來源:內克塔治療